ClinicalTrials.gg
RecruitingNCT07748520NESTINGUpdated Aug 5, 2026

Effect of Nesting During Intramuscular Injection on Pain, Stress, and Breastfeeding Success in Cesarean-Born Term Newborns

An interventional study of Nesting in Newborn Pain, Newborn Stress and Breastfeeding Success in Newborns, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged Up to 30 Minutes, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Oct 2025, registered Jul 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
Up to 30 Minutes
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Breast Feeding by Istanbul University - Cerrahpasa — 8 open to participants now, 8 under way, none of them phase 3. Breast Feeding · Istanbul University - Cerrahpasa.

Planned enrollment
6th of 15
112 · median 100
Started
2025
with 1 other
No phase
15 of 16
7 open now
Registered
13th of 16
by date

Among the 16 studies in Breast Feeding by Istanbul University - Cerrahpasa, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 15 with no phase, and was the 13th registered.

Breast Feeding

1,083 studies on the registry are indexed under Breast Feeding; 216 are open to participants now.

Browse Breast Feeding studies →

Open to participants now

8 of the 16 studies in Breast Feeding by Istanbul University - Cerrahpasa are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 125 Breast Feeding studies recruiting now, 65 (52%) set no upper age limit and 58 (46%) stop at 75 or younger; 52 take children under 18; 75 take healthy volunteers.

This study: Up to 30 Minutes · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Breast Feeding by Istanbul University - Cerrahpasa, or all of them as a file.
02

Study summary

This randomized controlled trial aims to evaluate the effect of nesting during the first intramuscular injection on pain, stress level, physiological parameters, settling time, and breastfeeding success in healthy term newborns delivered by cesarean section. A total of 112 newborns will be randomly assigned in a 1:1 ratio to either a nesting intervention group or a routine care control group. Newborns in the intervention group will receive nesting until the first intramuscular injection, whereas those in the control group will receive routine neonatal care. Pain, stress level, physiological parameters, settling time, and breastfeeding success will be evaluated using validated assessment tools. The findings are expected to provide evidence regarding the effectiveness of nesting as a simple, safe, and non-pharmacological intervention for reducing procedural pain and stress in newborns while supporting breastfeeding success.

Read the detailed description

Painful procedures performed during the first hours after birth, particularly intramuscular vitamin K and hepatitis B injections, are associated with significant pain and stress responses in newborns. Although several non-pharmacological interventions have been recommended to minimize procedural pain, evidence regarding the effectiveness of nesting in healthy term newborns delivered by cesarean section remains limited.

This study is designed as a prospective, single-center, parallel-group, randomized controlled trial. The study will be conducted in the newborn observation room of the Delivery Unit at Kocaeli Darıca Farabi Training and Research Hospital. Healthy term newborns (37-42 weeks of gestation) delivered by cesarean section will be enrolled after written informed parental consent is obtained. A total of 112 newborns will be randomly allocated in a 1:1 ratio to either the nesting intervention group or the routine care control group using Random Allocation Software.

Newborns assigned to the intervention group will be placed in a sterile cotton nesting position until the first intramuscular injection. Routine intramuscular administration of vitamin K and hepatitis B vaccine will be performed according to standard neonatal care. The control group will receive routine neonatal care without nesting. No additional invasive procedures will be performed for research purposes.

Pain, stress level, heart rate, respiratory rate, oxygen saturation, and settling time will be assessed before, during, and one minute after the injection. Breastfeeding success will be evaluated at the first breastfeeding after mother-infant reunion, at one hour after breastfeeding, and before hospital discharge using validated assessment tools. Outcome assessment will be performed by an independent assessor who is blinded to group allocation.

The primary objective of this study is to determine whether nesting reduces procedural pain and stress while improving physiological stability and breastfeeding success in term newborns delivered by cesarean section. The results are expected to contribute to evidence-based neonatal care by supporting the implementation of developmental, non-pharmacological interventions during routine newborn procedures.

03

Conditions studied

  • Newborn Pain
  • Newborn Stress
  • Breastfeeding Success in Newborns

Keywords

  • Nesting
  • Term Newborn
  • Cesarean Section
  • Intramuscular Injection
  • Newborn Pain
  • Newborn Stress
  • Breastfeeding Success
04

Who can participate

Ages eligible
Up to 30 Minutes
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written was obtained from the parent(s) or legal guardian(s) of the newborn.
  • Born by cesarean section.
  • Term newborn (gestational age between 37+0 and 41+6 weeks).
  • Birth weight between 2,500 g and 4,000 g.
  • Clinically stable vital signs (including heart rate, respiratory rate, and oxygen saturation).
  • No acute or chronic medical conditions.
  • No congenital anomalies.
  • No requirement for endotracheal intubation, resuscitation, or admission to the neonatal intensive care unit (NICU).
  • Scheduled to receive the first intramuscular injection after birth.

Exclusion criteria

Exclusion Criteria:

  • Multiple birth (e.g., twins or higher-order multiples).
  • Administration of vitamin K or vaccine before completion of the study procedures.
  • Withdrawal of parental consent at any time during the study.
  • Use of a pacifier, oral sucrose, or any pharmacological or non-pharmacological pain-relief intervention before completion of the outcome assessments.
  • Discharge from the hospital or transfer to another healthcare facility before completion of the study procedures.
  • Delayed mother-newborn reunion due to maternal general anesthesia or prolonged sedation following spinal or epidural anesthesia.
  • Delayed transfer of the newborn to the mother because of prolonged surgery, intraoperative complications, or delayed postoperative stabilization.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Nesting Group

    Term newborns delivered by cesarean section will receive the nesting intervention before and during routine intramuscular injection. Pain, stress level, and breastfeeding success will be assessed using validated outcome measures.

    Behavioral: Nesting

  • No intervention
    Standard Care Group

    Term newborns delivered by cesarean section will receive routine care during intramuscular injection without the nesting intervention. Pain, stress level, and breastfeeding success will be assessed using the same outcome measures.

Interventions

  • BehavioralNesting

    Nesting is a non-pharmacological positioning intervention in which the newborn is placed in a flexed, midline posture using rolled towels or positioning supports to provide containment before and during intramuscular injection. The intervention aims to reduce procedural pain and stress and improve breastfeeding success.

06

What researchers measure

Primary outcomes

  1. Neonatal Pain

    Pain will be assessed using the Neonatal Pain, Agitation and Sedation Scale (N-PASS). The pain/agitation component consists of five behavioral and physiological indicators, each scored from 0 to 2, yielding a total score ranging from 0 to 10. Higher scores indicate greater pain.

    Time frame: Immediately before intramuscular injection, during intramuscular injection, and 1 minute after intramuscular injection.

  2. Neonatal Stress Level

    Neonatal stress will be assessed using the Neonatal Stress Scale. The scale consists of eight behavioral and physiological indicators, each scored from 0 to 2, yielding a total score ranging from 0 to 16. Higher scores indicate greater neonatal stress.

    Time frame: Immediately before intramuscular injection, during intramuscular injection, and 1 minute after intramuscular injection.

Secondary outcomes

  1. Heart Rate

    Heart rate will be measured in beats per minute (bpm) to evaluate the newborn's physiological response to intramuscular injection. Higher heart rate values indicate a greater physiological response to procedural stress.

    Time frame: Immediately before intramuscular injection, during intramuscular injection, and 1 minute after intramuscular injection.

  2. Respiratory Rate

    Respiratory rate will be measured in breaths per minute (breaths/min) to evaluate the newborn's physiological response to intramuscular injection. Higher respiratory rate values indicate a greater physiological response to procedural stress.

    Time frame: Immediately before intramuscular injection, during intramuscular injection, and 1 minute after intramuscular injection.

  3. Peripheral Oxygen Saturation

    Peripheral oxygen saturation (SpO₂) will be measured using pulse oximetry and reported as a percentage (%) to evaluate the newborn's physiological response to intramuscular injection. Higher SpO₂ values indicate better oxygenation.

    Time frame: Immediately before intramuscular injection, during intramuscular injection, and 1 minute after intramuscular injection.

  4. Breastfeeding Success

    Breastfeeding success will be assessed using the Bristol Breastfeeding Assessment Tool (BBAT). The BBAT consists of four items (positioning, attachment, sucking, and swallowing), each scored from 0 to 2. Total scores range from 0 to 8, with higher scores indicating better breastfeeding effectiveness.

    Time frame: At the first breastfeeding following mother-newborn reunion, 1 hour after the first breastfeeding, and 48 hours after birth (prior to hospital discharge).

07

Study locations

1 of 1 sites recruiting
  • Kocaeli Darıca Farabi Training and Research Hospital
    Darıca, Kocaeli, Turkey (Türkiye)
    Recruiting
    • Emine Nur Çalımlı Celep, Msc · Contactenurcalimli@gmail.com · +90 506 126 48 03
    • Sevil İnal, Prof. Dr. · Principal investigator
    • Emine Nur Çalımlı Celep, Msc · Sub investigator
    • Yasemin Dinçel, Msc · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.

Of 505 non-industry interventional studies with no phase under Breast Feeding, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 12 months is close to that.

Counting every sponsor, half of 513 studies reached it within 12 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Aug 5, 2026
StartActual
Oct 15, 2025
Primary completionEst.
Oct 15, 2026
CompletionEst.
Oct 15, 2026
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07748520
Responsible party
Emine Nur Çalımlı Celep (PhD Student, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Aug 5, 2026
Start date
Oct 15, 2025
Primary completion
Oct 15, 2026 (estimated)
Completion
Oct 15, 2026 (estimated)
Last update
Aug 5, 2026

Study contacts

Emine Nur Çalımlı Celep, MSc
Contact
enurcalimli@gmail.com
+90 506 126 48 03
Yasemin Dinçel, MSc
Contact
yasemindincel96@gmail.com
+90 545 939 49 26
Sevil İnal, Prof. Dr.
principal investigator · Istanbul University-Cerrahpasa, Department of Midwifery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion